Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinomaChristoph Seidel, Viktor Grünwald, Martin Fenner et al.|European Journal of Cancer|2012Cited by 54
Temsirolimus in Daily Use: Results of a Prospective Multicentre Noninterventional Study of Patients with Metastatic Kidney CancerAndres Jan Schrader, Thomas Steiner, S. Seseke et al.|European Urology|2013Cited by 12